TABLE 26Haematological response to dasatinib in CML-AP: summary

StudyLength of follow-upDoseIMFComplete (n/N)Major (n/N)Minor (n/N)NEL (nIN)Overall (n/N)
Talpaz et al. (2006)104> 12 monthsa,bMixed/NRMixed5/11 = 45.5%9/11 = 81.8%0/11 = 00.0%4/11 = 36.4%
Cortes et al. (2007)3817 monthsaMixed/NRMixed14/22 = 63.6%16/22 = 72.7%
Guilhot et al. (2007)128 monthsc70 mg b.i.d.ImI3/8 = 37.5%5/8 = 62.5%2/8 = 25.0%2/8 = 25.0%7/8 = 87.5%
ImR39/99 = 39.4%64/99 = 64.6%16/99 = 16.2%25/99 = 25.3%80/99 = 80.8%
14 monthsa,d70 mg b.i.d.ImI6/13 = 46.2%9/13 = 69.2%3/13 = 23.1%12/13 = 92.3%
ImR72/161 = 44.7%102/161 = 63.4%30/161 = 18.6%126/161 = 78.3%
Kantarjian et al. (2009)8115 monthsa140 mg q.d.ImI16/41 = 39.0%31/41 = 75.6%15/41 = 36.6%36/41 = 87.8%
ImR59/117 = 50.4%74/117 = 63.2%15/117 = 12.8%83/117 = 70.9%
70 mg b.i.d.ImR23/43 = 53.5%29/43 = 67.4%6/43 = 14.0%34/43 = 79.1%
ImI59/116 = 50.9%79/116 = 68.1%20/116 = 17.2%83/116 = 71.6%

IMF, imatinib failure status; NEL, no evidence of leukaemia; NR, not reported.

a

Median follow-up.

b

Abstract states median follow-up ‘more than 12 months’, but precise data not given in text.

c

Minimum follow-up.

d

Data extracted from update publication.176

From: 2, Assessment of clinical effectiveness

Cover of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Myeloid Leukaemia: A Systematic Review and Economic Evaluation
Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Myeloid Leukaemia: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 16.22.
Rogers G, Hoyle M, Thompson Coon J, et al.
Southampton (UK): NIHR Journals Library; 2012 Apr.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.